Our targeted lytic peptide compounds address challenging clinical problems, representing significant global unmet medical needs.

AT-101
Lead compound, targeting luteinizing hormone releasing hormone (LHRH) receptors

AT-201
Targeting luteinizing hormone/chorionic gonadotropin (LH/CG) receptors

AT-301
Targeting tumors and tumor neo-vasculature via follicle stimulating hormone (FSH) receptors

AT-401
Antibody drug conjugates targeting CD20 and Her-2

A28 Therapeutics Pipeline

Learn Why Targeted Lytic Peptides Are a Promising Treatment for Multiple Cancer Types

Interested in learning more about the A28 targeted lytic peptide platform? We would be pleased to share our compelling story, platform, pipeline, and data with you.

Contact Us